Intellia Therapeutics Class Action Lawsuit
Analysis based on 50 articles · First reported Feb 11, 2025 · Last updated Apr 07, 2025
The class action lawsuit against Coya Therapeutics, coupled with the discontinuation of its NTLA-3001 program and workforce reduction, has led to a significant decline in its stock price. This event highlights the risks associated with pharmaceutical development and the importance of transparent communication for publicly traded companies in the biotechnology sector.
Coya Therapeutics is facing a class action lawsuit filed by law firms including Levi & Korsinsky, Rosen Law Firm, and The Gross Law Firm. The lawsuit alleges that Coya Therapeutics provided misleading information to investors between July 30, 2024, and January 8, 2025, concerning its Phase 1/2 study of NTLA-3001 for alpha-1 antitrypsin deficiency (AATD)-associated lung disease. The company had expressed confidence in its timeline for the study, expecting to dose the first patient in the second half of 2024. However, it allegedly failed to disclose the dwindling demand for viral-based editing methods, which made NTLA-3001 an inefficient program. On January 9, 2025, Coya Therapeutics announced a company reorganization, halting all NTLA-3001 research and studies and reducing its workforce by 27%. This news caused Coya Therapeutics' stock price to fall from $12.02 to $10.20 per share. Investors who suffered losses during this period have until April 14, 2025, to request to be appointed as lead plaintiff in the lawsuit.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard